<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; KERX</title>
	<atom:link href="http://www.stockbloghub.com/tag/kerx/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(KERX) Keryx Biopharmaceuticals Earns FDA Fast Track Status</title>
		<link>http://www.stockbloghub.com/2010/04/07/kerx-keryx-biopharmaceuticals-earns-fda-fast-track-status/33034</link>
		<comments>http://www.stockbloghub.com/2010/04/07/kerx-keryx-biopharmaceuticals-earns-fda-fast-track-status/33034#comments</comments>
		<pubDate>Wed, 07 Apr 2010 23:53:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33034</guid>
		<description><![CDATA[Keryx Biopharmaceuticals (KERX) received fast track status from the US Food and Drug Administration (FDA) for KRX-0401 (perifosine), which is being studied for treating refractory advanced colorectal cancer. This status is granted to drugs with the potential to treat serious or fatal conditions and qualify for a faster review process. Keryx plans to initiate a phase III trial of perifosine in the second quarter of 2010 under the FDA’s Special Protocol Assessment (SPA) program. The trial aims at comparing perifosine in combination with capecitabine (Xeloda) versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. The study is expected to be completed in the second half of 2011. Keryx plans to launch the drug by mid 2012. Although perifosine is the lead candidate at Keryx, it is also developing Zerenex ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/kerx-keryx-biopharmaceuticals-earns-fda-fast-track-status/33034/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Keryx Biopharmaceuticals&#8217; Loss Wider than Expected</title>
		<link>http://www.stockbloghub.com/2010/03/29/kerx-keryx-biopharmaceuticals-loss-wider-than-expected/32011</link>
		<comments>http://www.stockbloghub.com/2010/03/29/kerx-keryx-biopharmaceuticals-loss-wider-than-expected/32011#comments</comments>
		<pubDate>Mon, 29 Mar 2010 17:25:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32011</guid>
		<description><![CDATA[Keryx Biopharmaceuticals Inc.’s (KERX) fourth quarter net loss per share came in at 8 cents, wider than the Zacks Consensus Estimate of a loss of 6 cents. While fourth quarter net loss per share remained unchanged from the year ago period due to an increase in the number of shares, total net loss increased to $4.7 million during the reported quarter, compared to $3.8 million in the year-ago quarter. The company recorded no revenue in the reported quarter. The wider loss in the reported quarter was mainly attributable to higher spending on research and development, which tripled to $3.3 million from the year-ago quarter. Selling, general and administrative (SG&#38;A) costs for the reported quarter decreased approximately 41.4% year-over-year to $1.7 million. The sharp decline was attributable to the $1.4 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/kerx-keryx-biopharmaceuticals-loss-wider-than-expected/32011/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Healthcare Stock Watch: Short List of Booming (and Busting) Companies</title>
		<link>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406</link>
		<comments>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:11:08 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[QCOR]]></category>
		<category><![CDATA[Questcor Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25406</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 20, 2010: Issue #1179 On my way out to San Francisco last week, I never thought that I’d compare the biggest healthcare conference of the year to the dating scene. But that’s the overall vibe that I took away from the JP Morgan Healthcare Conference. The investors I spoke with reminded me of jilted lovers – eager to get back on the market, but scared to get hurt again. Rather than checking out the eligible candidates on Match.com, though, healthcare investors spend their time poring over companies’ balance sheets and drug pipelines. And so it was in San Francisco. Everyone wanted to be optimistic, but that optimism was only expressed in private conversations. When I saw the same investors in front of companies’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Keryx Biopharmaceuticals Cancer Drug Impresses</title>
		<link>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474</link>
		<comments>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474#comments</comments>
		<pubDate>Sat, 03 Oct 2009 22:08:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aeterna Zentaris Inc]]></category>
		<category><![CDATA[AEZS]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16474</guid>
		<description><![CDATA[Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the US, Canada and Mexico. The data was presented at the eighth International Kidney Cancer Symposium in Chicago. The candidate demonstrated efficacy, safety and tolerability in metastatic renal cell carcinoma (RCC) patients whose disease progressed after failing treatment with both a VEGF (vascular endothelial growth factor) receptor inhibitor and an mTOR (mammalian target of rapamycin) inhibitor. Even though the drug was well-tolerated, the most common adverse events were gastrointestinal discomfort and fatigue. RCC is the most common of all kidney tumors, accounting for 85% of the cases. The advanced form of the disease is resistant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/kerx-keryx-biopharmaceuticals-cancer-drug-impresses/16474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

